The study of efficacy of AT1 receptor blocker, olmesartan and calcium antagonists , azelnidipine combination therapy in patients with essential hypertension , diabetic or chronic kidney disease

Trial Profile

The study of efficacy of AT1 receptor blocker, olmesartan and calcium antagonists , azelnidipine combination therapy in patients with essential hypertension , diabetic or chronic kidney disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 May 2016

At a glance

  • Drugs Azelnidipine (Primary) ; Olmesartan medoxomil (Primary)
  • Indications Diabetes mellitus; Essential hypertension; Renal failure
  • Focus Therapeutic Use
  • Acronyms HARIMAYA study
  • Most Recent Events

    • 19 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top